Precision medicine: Towards the implementation of molecular diagnosis in the Basque Country to obtain biomarkers

The project's aim is that if someone were to develop diabetes, for example, in 2025, it would be possible to retrieve their past data and determine if there were any early indicators. This could be extremely helpful in identifying similar patients at risk. The accumulation of genotypic and phenotypic data, along with environmental and lifestyle factors from healthy individuals and potentially those with the disease, will provide a comprehensive understanding of how the disease will manifest and how it will respond to treatment. This project will lay the groundwork for large-scale scientific phenotyping studies on a very broad individual basis (light phenotyping) and on a niche level for smaller, more specific groups (deep phenotyping).

The BG19 project aims to create a database containing relevant medical information from healthy individuals (10,000 employees, representing 30% of the Mondragón Corporation's employees in the Basque Country) who are representative of the Basque population. This database will include data obtained from the analysis of human biospecimens (urine, serum, feces, and saliva) using omics techniques (metabolomics, proteomics, genomics, microbiota, etc.).

The data obtained will be processed in an anonymized and secure manner to establish general parameters, identify individuals who deviate from the average, and observe how variables change over time.

The bG19 project proposes that the Basque health service be a reference actor in the ongoing digital transformation, equip itself with health management tools that are as close as possible to its citizens, and promote the development of a new economy through the integration and creation of a dossier of biological and lifestyle data of healthy people, using Artificial Intelligence algorithms.